IRCCS Stella Maris Foundation, Calambrone, via dei Giacinti 2, 56128, Pisa, Italy.
Child Neurology, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.
J Neurol. 2022 Jan;269(1):437-450. doi: 10.1007/s00415-021-10792-3. Epub 2021 Sep 6.
Monoallelic variants in the KIF1A gene are associated with a large set of clinical phenotypes including neurodevelopmental and neurodegenerative disorders, underpinned by a broad spectrum of central and peripheral nervous system involvement.
In a multicenter study conducted in patients presenting spastic gait or complex neurodevelopmental disorders, we analyzed the clinical, genetic and neuroradiological features of 28 index cases harboring heterozygous variants in KIF1A. We conducted a literature systematic review with the aim to comparing our findings with previously reported KIF1A-related phenotypes.
Among 28 patients, we identified nine novel monoallelic variants, and one a copy number variation encompassing KIF1A. Mutations arose de novo in most patients and were prevalently located in the motor domain. Most patients presented features of a continuum ataxia-spasticity spectrum with only five cases showing a prevalently pure spastic phenotype and six presenting congenital ataxias. Seventeen mutations occurred in the motor domain of the Kinesin-1A protein, but location of mutation did not correlate with neurological and imaging presentations. When tested in 15 patients, muscle biopsy showed oxidative metabolism alterations (6 cases), impaired respiratory chain complexes II + III activity (3/6) and low CoQ10 levels (6/9). Ubiquinol supplementation (1gr/die) was used in 6 patients with subjective benefit.
This study broadened our clinical, genetic, and neuroimaging knowledge of KIF1A-related disorders. Although highly heterogeneous, it seems that manifestations of ataxia-spasticity spectrum disorders seem to occur in most patients. Some patients also present secondary impairment of oxidative metabolism; in this subset, ubiquinol supplementation therapy might be appropriate.
KIF1A 基因的单等位基因变异与包括神经发育和神经退行性疾病在内的一系列临床表型相关,其基础是广泛的中枢和外周神经系统受累。
在一项针对表现出痉挛性步态或复杂神经发育障碍的患者进行的多中心研究中,我们分析了 28 名携带 KIF1A 杂合变异的索引病例的临床、遗传和神经影像学特征。我们进行了一项文献系统综述,旨在将我们的发现与先前报道的 KIF1A 相关表型进行比较。
在 28 名患者中,我们确定了 9 种新的单等位基因变异,1 种涉及 KIF1A 的拷贝数变异。大多数患者的突变是从头发生的,并且主要位于运动结构域。大多数患者表现出连续性共济失调-痉挛谱的特征,只有 5 例表现出主要的纯痉挛表型,6 例表现出先天性共济失调。17 种突变发生在 Kinesin-1A 蛋白的运动结构域,但突变位置与神经和影像学表现无关。在 15 名患者中进行检测时,肌肉活检显示氧化代谢改变(6 例)、呼吸链复合物 II+III 活性受损(3/6)和 CoQ10 水平降低(6/9)。6 名患者使用了(每天 1 克)泛醇补充剂,有主观受益。
本研究拓宽了我们对 KIF1A 相关疾病的临床、遗传和神经影像学认识。尽管高度异质性,但似乎在大多数患者中出现了共济失调-痉挛谱疾病的表现。一些患者还存在继发性氧化代谢受损;在这一组中,泛醇补充治疗可能是合适的。